The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Bookman, M A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Angiogenesis; Carboplatin; Chemotherapy; Chemotherapy resistance; Dose density; Ovarian carcinoma

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOXANTRONE; MONOCLONAL ANTIBODY IMC 1C11; OLAPARIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; TOPOTECAN; VALSPODAR;

BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DNA DAMAGE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EXCISION REPAIR; HUMAN; MAINTENANCE THERAPY; NEOVASCULARIZATION (PATHOLOGY); OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA;

CALIBRATION; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; STANDARD OF CARE;

EID: 78649384084     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq368     Document Type: Conference Paper

References (55)

1. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
2. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-717.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
4. du Bois A, Luck HJ, Meier W et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
5. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997; 15: 193-198.
6. Gore M, Mainwaring P, A'Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16: 2426-2434.
7. Möbus V, Wandt H, Frickhofen N et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193.
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European- Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
9. Omura GA, Brady MF, Look KY et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinumpretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003; 21: 2843-288.
10. Bolis G, Scarfone G, Polverino G et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22: 686-690.
11. Markman M, Rose PG, Jones E et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 1998; 16: 1849-1851.
12. Spriggs DR, Brady MF, Vaccarello L et al. Phase III randomized trial of intravenous cisplatin plus a 24or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 4466-4471.
13. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-192.
14. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-440.
15. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
16. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
17. du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127-1135.
18. Kristensen GB, Vergote I, Stuart G et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003; 13 (Suppl 2): 17217-7.
19. Hoskins PJ, Vergote I, Stuart G et al. Phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol 2008; 26: abstract LBA5505.
20. Scarfone G, Scambia G, Raspagliesi F et al. A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor >1 cm after primary surgery) and IV ovarian cancer (OC). J Clin Oncol 2006; 24 (18 Suppl): abstract 5003.
21. Bookman MA, Brady MF, McGuire W et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup (GCIG). J Clin Oncol 2009; 27: 1419-1425.
22. Guminski AD, Harnett PR, deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line-a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 2001; 48: 229-234.
23. du Bois A, Kristensen G, Joly F et al. Randomized phase-III GCIG study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) vs. Paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC). 12th Biennial Meeting of the International Gynecological Cancer Society, 2008: abstract 480.
24. Pujade-Lauraine E, Mahner S, Kaern J et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 2009: 27 (18 Suppl): abstract LBA5509.
25. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159.
26. Glinsky GV. 'Stemness' genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008; 26: 2846-2853.
27. Bolis G, Danese S, Tateo S et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 74-78.
28. Pfisterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98: 1036-1045.
29. De Placido S, Scanbia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004; 22: 2635-2642.
30. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
31. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinumbased intravenous chemotherapy. Int J Gynecol Cancer 2003; 13 (Suppl 2): 196-203.
32. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-634.
33. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497.
34. Vergote I, Trope CG, Amant F et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). 12th Biennial Meeting of the International Gynecological Cancer Society, 2008: abstract 1767.
35. Singer G, Stöhr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-224.
36. Pohl G, Ho CL, Kurman RJ et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000.
37. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005; 24: 7443-7454.
38. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
39. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
40. Winter WE 3rd, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-3627.
41. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
42. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-71.
43. Burger RA, Brady ML, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; 28 (suppl): abstract LBA1.
44. Gore ME, Atkinson RJ, Thomas H et al. A phase II trial of ZD0473 in platinumpretreated ovarian cancer. Eur J Cancer 2002; 38: 2416-2420.
45. Fracasso PM, Blessing JA, Morgan MA et al. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 2856-2859.
46. Glasspool RM, Gore M, Rustin G et al. Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. Clin Oncol 2009; 27 (15 Suppl): abstract 5562.
47. Ak Holzer, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006; 66: 10944-10952.
48. Lhommé C, Joly F, Walker JL et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008; 26: 2674-2682.
49. De Geest K, Blessing JA, Morris RT et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinumand taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2010; 28: 149-153.
50. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
51. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
52. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
53. Hilton JL, Geisler JP, Rathe JA et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94: 1396-1406.
54. Edwards SL, Brough R, Lord CJ. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115.
55. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.